Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 1/20 | 0.50 |
| ▸ | KCNQ4 | P56696 | 3/20 | 0.41 |
| ▸ | KCNQ5 | Q9NR82 | 3/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | METAP1 | P53582 | 1/20 | 0.37 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | ESRRG | P62508 | 1/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.36 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29956067 | 1.00 | CYP17A1 (0.50) | CYP17A1KCNQ4KCNQ5RXFP1CA12 | |
| SCHEMBL3784938 | 0.87 | HPGD (0.44) | CYP17A1KCNQ4KCNQ5RXFP1CA12 | |
| SCHEMBL21682754 | 0.84 | SMN1; SMN2 (0.44) | CYP17A1KCNQ4KCNQ5RXFP1CA12 | |
| SCHEMBL857284 | 0.82 | HTT (0.55) | CYP17A1KCNQ4KCNQ5HTTLMNA | |
| SCHEMBL15925258 | 0.82 | CYP17A1 (0.54) | CYP17A1KCNQ4KCNQ5RXFP1CA12 | |
| SCHEMBL169631 | 0.82 | HTT (0.44) | HTTLMNAPOLBNPSR1 | |
| SCHEMBL29952945 | 0.81 | LMNA (0.41) | RXFP1CA12CA1CA9HIF1A | |
| SCHEMBL2363945 | 0.81 | CYP17A1 (0.53) | CYP17A1KCNQ4KCNQ5RXFP1HTT | |
| SCHEMBL29834708 | 0.81 | CYP17A1 (0.53) | CYP17A1KCNQ4KCNQ5RXFP1HTT | |
| SCHEMBL6134887 | 0.81 | ATR (0.45) | CYP17A1RXFP1CA12CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4665373-A2 | SELECT THIOSTREPTON-INSPIRED COMPOUNDS FOR TREATMENT OF CANCER AND PREPARATION THEREOF | RS Oncology, LLC (US) | 2025-12-24 | — | — | EP | disclosed |
| US-20250381278-A1 | PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER | UNIV WAKE FOREST HEALTH SCIENCES (US) | 2025-12-18 | — | — | US | disclosed |
| US-20250144078-A1 | THIOSTREPTON-INSPIRED COMPOUNDS FOR TREATMENT OF CANCER AND PREPARATION THEREOF | SYMERES NETHERLANDS B.V. (NL) | 2025-05-08 | — | — | US | disclosed |
| US-20250011316-A1 | PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER | WAKE FOREST UNIVERSITY HEALTH SCIENCES | 2025-01-09 | — | — | US | disclosed |
| EP-4479390-A2 | THIOSTREPTON-INSPIRED COMPOUNDS FOR TREATMENT OF CANCER AND PREPARATION THEREOF | RS Oncology, LLC (US) | 2024-12-25 | — | — | EP | disclosed |
| WO-2024173644-A2 | SELECT THIOSTREPTON-INSPIRED COMPOUNDS FOR TREATMENT OF CANCER AND PREPARATION THEREOF | RS ONCOLOGY, LLC (US) | 2024-08-22 | — | — | WO | disclosed |
| WO-2023158679-A2 | THIOSTREPTON-INSPIRED COMPOUNDS FOR TREATMENT OF CANCER AND PREPARATION THEREOF | RS ONCOLOGY, LLC (US) | 2023-08-24 | — | — | WO | disclosed |
| WO-2023158679-A2 | THIOSTREPTON-INSPIRED COMPOUNDS FOR TREATMENT OF CANCER AND PREPARATION THEREOF | RS ONCOLOGY, LLC (US) | 2023-08-24 | — | — | WO | disclosed |
| EP-3252050-B1 | PHTHALAZINONES AND ISOQUINOLINONES AS ROCK INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-02-26 | — | — | EP | disclosed |
| US-10385026-B2 | Phthalazinones and isoquinolinones as rock inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-08-20 | — | — | US | disclosed |
| US-20060040973-A1 | 1-Aminoisoindolyl derivatives and 3-amino- and 3-hydroxy- indazolyl-, benzisoxazolyl, and benzisothiazolyl- derivatives, e.g., 3-(3'-Aminobenzisoxazol-5'-yl)-5-[(2'-aminosulfonyl-[1,1']-biphen-4-yl)aminocarbonyl]-5-methylisoxazoline; treating thromboembolic disorders | LAM PATRICK Y | 2006-02-23 | — | — | US | disclosed |
| US-6958356-B2 | Guanidine mimics factor Xa inhibitors | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-10-25 | — | — | US | disclosed |
| EP-0991638-B1 | NOVEL GUANIDINE MIMICS AS FACTOR Xa INHIBITORS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2005-08-17 | — | — | EP | disclosed |
| WO-2005062847-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-07-14 | — | — | WO | disclosed |
| US-6906070-B2 | Anticoagulants | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-06-14 | — | — | US | disclosed |
| US-20030069258-A1 | Novel guanidine mimics factor Xa inhibitors | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-04-10 | — | — | US | disclosed |
| US-20020025963-A1 | Novel guanidine mimics as factor Xa inhibitors | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-02-28 | — | — | US | disclosed |
| US-6339099-B1 | FOR THERAPY AND PROPHYLAXIS OF THROMBOEMBOLIC DISORDER | DUPONT PHARMACEUTICALS COMPANY | 2002-01-15 | — | — | US | disclosed |
| EP-0991638-A1 | NOVEL GUANIDINE MIMICS AS FACTOR Xa INHIBITORS | Du Pont Pharmaceuticals Company (US) | 2000-04-12 | — | — | EP | disclosed |
| WO-1998057951-A1 | NOVEL GUANIDINE MIMICS AS FACTOR Xa INHIBITORS | DU PONT PHARMACEUTICALS COMPANY (US) | 1998-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040973-A1 | 1-Aminoisoindolyl derivatives and 3-amino- and 3-hydroxy- indazolyl-, benzisoxazolyl, and benzisothiazolyl- derivatives, e.g., 3-(3'-Aminobenzisoxazol-5'-yl)-5-[(2'-aminosulfonyl-[1,1']-biphen-4-yl)aminocarbonyl]-5-methylisoxazoline; treating thromboembolic disorders | SERPINC1, F7, SERPINE1 | CYP17A1 3384/4885KCNQ4 1350/4885KCNQ5 872/4885 |
| US-20030069258-A1 | Novel guanidine mimics factor Xa inhibitors | TFPI, F11, F12 | CYP17A1 1946/4885KCNQ4 2770/4885KCNQ5 2351/4885 |
| US-10385026-B2 | Phthalazinones and isoquinolinones as rock inhibitors | MYLK, MYLK2, ROCK1 | CYP17A1 1132/4885KCNQ4 2234/4885KCNQ5 1505/4885 |
| US-20250011316-A1 | PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER | PRDX1, PRDX2, PRDX6 | CYP17A1 609/4885KCNQ4 4383/4885KCNQ5 3960/4885 |
| US-20250144078-A1 | THIOSTREPTON-INSPIRED COMPOUNDS FOR TREATMENT OF CANCER AND PREPARATION THEREOF | TYMS, TOP1, TOP2A | CYP17A1 3920/4885KCNQ4 4768/4885KCNQ5 4690/4885 |
| US-20020025963-A1 | Novel guanidine mimics as factor Xa inhibitors | F11, SERPINC1, TFPI | CYP17A1 1295/4885KCNQ4 3215/4885KCNQ5 2777/4885 |
| US-20250381278-A1 | PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER | PRDX1, PRDX2, PRDX6 | CYP17A1 499/4885KCNQ4 4424/4885KCNQ5 3997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.